Leading the Way in Life Science Technologies

GEN Exclusives

More »

Best of the Web

More »
Feb 01, 2005 (Vol. 25, No. 3)

NIH Roadmap Home Page

URL:nihroadmap.nih.gov
  • Overview
  • Not much science
Well, I think we can all see where this one is headed. Get it? OK, bad pun, but the truth is, that’s not a bad description of what this site is aimed at doing—showing direction for NIH-funded research. According to information at the site, the NIH Roadmap “is an innovative approach to accelerate fundamental discovery and translation of that knowledge into effective prevention strategies and new treatments.” Initiatives described at the site include three broad themes: New Pathways to Discovery, Research Teams of the Future, and Re-engineering the Clinical Research Enterprise.” The site provides links to funding opportunities within these initiatives, descriptions of previously funded research, FAQs, and News/Information. An interesting read.
  • Key:
  • Strong Points
  • Weak Points
  • Ratings:
  • Excellent
  • Very Good
  • Good


*The opinions expressed are solely those of the author(s) and should not be construed as reflecting the viewpoints of the publisher, Genetic Engineering & Biotechnology News, Mary Ann Liebert, Inc., the publishing house, or employees and affiliates thereof.

Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »